ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Scientist, Bioconjugation at Dyne Therapeutics - ApplyBlast

Scientist, Bioconjugation

Dyne Therapeutics

1 month ago

4.1 on Glassdoor

Waltham, Massachusetts, United States

Onsite

Full Time

Junior

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

The Scientist, Bioconjugation at Dyne Therapeutics designs, synthesizes, purifies, and characterizes novel bioconjugates to support the company's therapeutic pipeline for neuromuscular diseases. The role applies expertise in bioconjugation chemistry, protein purification, and analytical characterization, collaborating with cross‑functional teams to advance candidates from discovery through development.

Responsibilities

Design and conduct experiments to synthesize and optimize bioconjugates
Purify and characterize bioconjugates using chromatographic and spectroscopic methods
Collaborate with cross‑functional teams to advance therapeutic candidates

Skills

Qualifications

PhD in chemistryPhD in biochemistryPhD in chemical biologyPhD in pharmaceutical sciencesMaster’s degree

About Dyne Therapeutics

dyne-tx.com

Headquarters

Waltham, Massachusetts, United States

Company Size

51-200 employees

Founded

2018

View Profile

Dyne Therapeutics is a biotechnology company developing nucleic acid–based therapies for genetically driven neuromuscular diseases. Leveraging its proprietary FORCE™ platform, Dyne aims to address the root cause of disease and deliver functional improvement for people living with conditions such as Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD). The company advances a pipeline of therapeutics from discovery through clinical development with the mission of transforming the lives of patients with rare neuromuscular diseases.